PMID- 35860003
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231221
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Cantharidin Inhibits Proliferation of Liver Cancer by Inducing DNA Damage via 
      KDM4A-Dependent Histone H3K36 Demethylation.
PG  - 2197071
LID - 10.1155/2022/2197071 [doi]
LID - 2197071
AB  - OBJECTIVE: To investigate the effect of cantharidin on DNA damage in 
      hepatocellular carcinoma cells and its possible mechanism. METHODS: Cell 
      proliferation assay and terminal deoxynucleotidyl transferase-mediated dUTP nick 
      end labeling (TUNEL) assay were used to analyze the effects of cantharidin on 
      cell proliferation and apoptosis of hepatocellular carcinoma cells. The 
      expression levels of DNA damage markers H2AX and P21 were analyzed by qRT-PCR. 
      The expression of KDM4A and H3K36me3 was observed by western blot. The expression 
      of KDM4A was regulated by siRNA or plasmid transfection. The effect of KDM4A on 
      DNA damage induced by cantharidin in liver cancer was observed after 
      overexpression and addiction of KDM4A. RESULTS: Cantharidin can significantly 
      inhibit the growth of hepatocellular carcinoma cells and induce apoptosis of 
      hepatocellular carcinoma cells. Cantharidin enhances the chemotherapy sensitivity 
      of liver cancer by targeting the upregulation of KDM4A and the regulation of DNA 
      damage induced by H3K36me3. Overexpression of KDM4A enhances DNA damage induced 
      by cantharidin in HCC. KDM4A silencing attenuated the damage of cantharidin to 
      the DNA of HCC cells. CONCLUSION: Cantharidin can inhibit the growth and promote 
      apoptosis of hepatocellular carcinoma cells. Meanwhile, cantharidin can induce 
      DNA damage in HCC cells. Mechanism studies have shown that cantharidin induces 
      DNA damage through the demethylation of KDM4A-dependent histone H3K36.
CI  - Copyright (c) 2022 Chao Wei et al.
FAU - Wei, Chao
AU  - Wei C
AD  - Infectious Disease Department, Qijiang Hospital of the First Affiliated Hospital 
      of Chongqing Medical University, Chongqing 401420, China.
FAU - Deng, Xiangui
AU  - Deng X
AD  - Infectious Disease Department, Wenlong Hospital of Qijiang, Chongqing 401420, 
      China.
FAU - Gao, Shudi
AU  - Gao S
AD  - Infectious Disease Department, Taiyuan Hospital of Traditional Chinese Medicine, 
      Taiyuan 030009, Shanxi Province, China.
FAU - Wan, Xuemei
AU  - Wan X
AD  - Infectious Disease Department, Affiliated Hospital of Chengdu University of 
      Traditional Chinese Medicine, Chengdu 610032, Sichuan Province, China.
FAU - Chen, Jing
AU  - Chen J
AUID- ORCID: 0000-0002-9757-6027
AD  - Infectious Disease Department, Affiliated Hospital of Chengdu University of 
      Traditional Chinese Medicine, Chengdu 610032, Sichuan Province, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220711
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2023 Dec 13;2023:9785474. PMID: 38125128
PMC - PMC9293552
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/07/22 06:00
MHDA- 2022/07/22 06:01
PMCR- 2022/07/11
CRDT- 2022/07/21 02:23
PHST- 2022/03/16 00:00 [received]
PHST- 2022/05/19 00:00 [revised]
PHST- 2022/05/27 00:00 [accepted]
PHST- 2022/07/21 02:23 [entrez]
PHST- 2022/07/22 06:00 [pubmed]
PHST- 2022/07/22 06:01 [medline]
PHST- 2022/07/11 00:00 [pmc-release]
AID - 10.1155/2022/2197071 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Jul 11;2022:2197071. doi: 
      10.1155/2022/2197071. eCollection 2022.